To determine whether hypoalbuminemia is an independent risk factor for poor outcome in the acutely ill, and to assess the potential of exogenous albumin administration for improving outcomes in hypoalbuminemic patients.
Objective
To determine whether hypoalbuminemia is an independent risk factor for poor outcome in the acutely ill, and to assess the potential of exogenous albumin administration for improving outcomes in hypoalbuminemic patients.
Summary Background Data
Hypoalbuminemia is associated with poor outcomes in acutely ill patients, but whether this association is causal has remained unclear. Trials investigating albumin therapy to correct hypoalbuminemia have proven inconclusive.
Methods
A meta-analysis was conducted of 90 cohort studies with 291,433 total patients evaluating hypoalbuminemia as an outcome predictor by multivariate analysis and, separately, of nine prospective controlled trials with 535 total patients on correcting hypoalbuminemia.
Results
Hypoalbuminemia was a potent, dose-dependent independent predictor of poor outcome. Each 10-g/L decline in serum albumin concentration significantly raised the odds of mortality by 137%, morbidity by 89%, prolonged intensive care unit and hospital stay respectively by 28% and 71%, and increased resource utilization by 66%. The association between hypoalbuminemia and poor outcome appeared to be independent of both nutritional status and inflammation. Analysis of dose-dependency in controlled trials of albumin therapy suggested that complication rates may be reduced when the serum albumin level attained during albumin administration exceeds 30 g/L.
Conclusions
Hypoalbuminemia is strongly associated with poor clinical outcomes. Further well-designed trials are needed to characterize the effects of albumin therapy in hypoalbuminemic patients. In the interim, there is no compelling basis to withhold albumin therapy if it is judged clinically appropriate.
The normal serum concentration of albumin in healthy adults is approximately 35 to 50 g/L. Diminished circulating level of albumin-hypoalbuminemia-is common in seriously ill patients. For instance, the reported frequency of hypoalbuminemia, defined as a serum albumin concentration of less than 34 g/L, was 21% at the time of admission in adult hospitalized patients. 1 After admission, worsening of existing hypoalbuminemia and development of de novo hypoalbuminemia are both frequently encountered. 2 The increased likelihood of poor outcomes such as mortality, morbidity, and prolonged intensive care unit (ICU) and hospital stay in acutely ill patients with hypoalbuminemia is well recognized. 3, 4 Because of its importance as an outcome predictor, serum albumin level has been added as one of the component parameters in the Acute Physiology and Chronic Health Evaluation (APACHE) III score. 5 The association between hypoalbuminemia and poor outcomes has long motivated clinicians in administering exogenous albumin to hypoalbuminemic patients, 4 and hypoalbuminemia is a licensed indication for human albumin in the United States and other countries. However, the appropriateness of this practice has been challenged on the basis of insufficient evidence to support its efficacy. 4, 6 At the heart of the controversy is causality-whether hypoalbuminemia directly contributes to poor outcomes, in which case albumin replacement therapy might bestow benefit, or merely serves as a marker for other "upstream" pathologic processes such as malnutrition or inflammation, in which case exogenous albumin might be ineffective in altering the clinical course of the patient. Two types of currently available evidence might help elucidate the appropriateness of albumin replacement therapy for hypoalbuminemia: results from multivariate analysis of cohort study data collected for the purpose of evaluating the relationship between albumin level and outcome specifically in acutely ill patients, and findings of controlled trials evaluating the effects of correcting hypoalbuminemia on morbidity. Such evidence has not previously been systematically reviewed.
Multivariate analysis is crucial to an epidemiologic inquiry into causality, since it can directly address whether other risk factors satisfactorily explain the hypoalbuminemia effect and can provide more accurate estimates for the strength of the hypoalbuminemia effect and the dose-response relationship between endogenous serum albumin level and outcome. Lack of detectable confounding, strength of association, and dose-response relationship, as well as plausible biologic mechanisms, are the principal epidemiologic criteria for evaluating causality. 7 Multivariate analysis has been reported on voluminous data generated in cohort studies examining the effects of hypoalbuminemia on a variety of clinical outcomes in the acutely ill. The preponderance of this evidence has been published only recently.
Two recent meta-analyses failed to detect a significant effect of albumin administration on survival in randomized controlled trials of hypoalbuminemic patients. 8, 9 However, in these trials the numbers of patients enrolled were small. Furthermore, the reported mortality rate in the control group was only 10% to 12%. Consequently, mortality was a relatively insensitive endpoint in this patient population. Complications, on the other hand, are substantially more frequent than deaths, and thus morbidity may serve as a more sensitive indicator for the effects of administered albumin. In addition, morbidity is a major concern of patients. 10 Through systematic review, we have endeavored to identify all cohort studies with multivariate analysis of serum albumin level as an outcome predictor and all controlled trials on correction of hypoalbuminemia. We here report the results of a meta-analysis encompassing both types of investigations.
MATERIALS AND METHODS

Inclusion Criteria
For inclusion, cohort studies must have focused on serum albumin as an outcome predictor in the acutely ill and entailed multivariate analysis by methods such as logistic regression or Cox proportional hazards regression. No restrictions were placed on the types of acute illnesses or outcomes addressed. Thus, we adopted broad inclusion criteria. Views differ as to the optimal scope for meta-analyses; however, broad meta-analyses have been advocated on the basis of their statistical power and generalizability. 11 Published and unpublished prospective controlled trials were included if they were designed to evaluate the effects of correcting existing hypoalbuminemia in the acutely ill. Morbidity data must have been available. Trials of hypoalbuminemia prevention in patients with normal serum albumin levels at study entry were not included. A randomized design was not required. The control group must have received either crystalloid or no albumin. Trials comparing albumin with synthetic colloids, blood products, or plasma protein fraction as the control regimen were not included.
Search Techniques
Relevant studies were sought without language restriction by computer searches of the MEDLINE and EMBASE bibliographic databases, the Cochrane Controlled Trials Register, and the Cochrane Medical Editors Trial Amnesty of unpublished trials. Additional Internet-resident resources such as conference reports, abstracts, reference compilations, and full-text journal articles were located using the Altavista, Northernlight, Hotbot, Excite, and Google search engines. We searched the Journal of the American Medical Association, the New England Journal of Medicine, The Lancet, and the British Medical Journal by hand for the period from January 1990 to May 2002 and Index Medicus for the years 1940 through 1965. We also consulted the authors of published controlled trial reports related to albumin and the medical directors of albumin suppliers and examined the reference citations from completed reviews and protocols in the Cochrane Database of Systematic Reviews, other meta-analyses, review articles, and reports of controlled and uncontrolled studies involving albumin.
Data Collection
Two investigators independently selected studies and extracted data. Disparities in selection and extraction decisions were resolved through discussion. In controlled trials, complications were scored on an intention-to-treat basis.
Statistical Analysis
Individual study results were expressed as odds ratios (OR) with 95% confidence intervals (CI). To allow for between-study statistical heterogeneity, OR estimates were quantitatively combined under a random effects model. OR values more than 1 signify an increased probability of poor outcome.
Most multivariate analyses from cohort studies were performed by either logistic regression or Cox regression. Exponentiated coefficients from these two types of analysis provide an OR and hazard ratio, respectively, for the outcome of interest. These two effect size metrics, though distinct, have been shown both theoretically and empirically to be similar in magnitude under a range of conditions. 12, 13 We use the term OR to denote both these effect size measures. Logistic regression and Cox regression models can accommodate both continuous variables such as serum albumin level or body mass index and binary indicator variables such as the presence of chronic renal disease or diabetes. The OR corresponding to the impact of hypoalbuminemia on a particular endpoint is adjusted during the estimation process to account for the effects of the other explanatory model variables.
In some included cohort studies OR was reported on the basis of broad serum albumin cutoffs (e.g., Ͻ35 vs. Ն35 g/L). In such cases we used the provided OR value and estimates of the median serum albumin values within the two cutoff ranges to calculate OR for each 10-g/L decrement in serum albumin. 14 The median values were wherever possible estimated from within-study data on the distribution of serum albumin concentrations and otherwise from comparable studies in the same or similar clinical indications. In a few cohort studies OR values for each of several serum albumin levels were supplied, and OR per 10-g/L serum albumin decline was estimated by weighted leastsquares regression. 15 When P values were the only measures of precision reported, the test-based CI was calculated. 14 For cohort studies we employed the META computer program 16 to calculate pooled estimates of OR and CI and evaluate heterogeneity.
For prospective controlled studies, the primary outcome measure was the OR for occurrence of one or more complications in individual patients. The METAN computer program 17 was used to calculate OR and CI for individual studies, assess heterogeneity, and derive pooled estimates of OR and CI across studies. Because of pre-existing evidence indicating a dose-response relationship between albumin level and outcome, 18 the analysis plan also called a priori for an evaluation of outcome in relation to the mean peak serum albumin level attained during albumin therapy. This evaluation was performed by meta-analysis regression 19 using the METAREG program. 20 Publication bias in controlled trials was assessed by the method of Egger et al 21 using the METABIAS program. 22 The methodologic quality of controlled trials was appraised on the basis of blinding, the presence of morbidity as a study endpoint, and between-group crossover by one or more patients. In the case of randomized controlled trials, the allocation concealment method was classified as adequate, inadequate, or unclear. 23 
RESULTS
Cohort Studies
Ninety cohort studies fulfilling the inclusion criteria were identified (Table 1) . 1,2,18,24 -110 The total number of patients in the 90 studies was 291,433 and the median number of patients per study was 281 (range 215) . Forty-nine of the studies, with 200,413 patients, representing 69% of the total patient population, were published since 1998. Thirty studies involved hospitalized patients in general, 11 cardiac surgery, 12 noncardiac surgery, and 37 renal dysfunction. The total numbers of patients in the respective categories were 27,730, 39,080, 65,828 and 158,795. The median patient age across all included studies was 60 years (range 10 -89), and the median percentage of males in the study populations was 55% (range 26 -100%).
Forty-one included studies were prospective and 45 were retrospective. Four studies involved both prospective and retrospective components. Five studies were multicenter investigations.
Multivariate analysis was conducted by logistic regression in 40 studies, Cox regression in 36, and both in 1. OR and CI could be extracted or derived from the reports of 67 studies. The remaining 23 studies either did not supply the necessary data or employed a type of multivariate analysis that does not yield an OR estimate. Hence, data from these 23 included studies could not be quantitatively combined.
The median number of covariates (i.e., variables in addition to albumin evaluated for inclusion in the multivariate models) per study was 11 (range 1-124). Mortality was an endpoint of 66 studies, morbidity of 27, hospital stay of 9, ICU stay of 3, resource utilization (i.e., ventilatory support, transfusion or hospitalization) of 9, treatment failure of 2, quality of life of 1, and overmedication of 1. A single endpoint was subjected to multivariate analysis in 71 studies, 2 endpoints in 14 studies, 3 in 3 studies, and 5 in 2 studies. The total number of multivariate analyses among all 90 studies was 118.
The strength of association between serum albumin and outcome was reported for 26 final multivariate models. The median rank of albumin, from strongest to weakest predictor, versus all other covariates included in the final models was 2 (range 1-11). The median number of covariates in these final models, not counting albumin itself, was 5 (range 1-24). Thus, albumin was among the most powerful outcome predictors.
In eight analyses both univariate and multivariate OR estimates were provided for the association between serum albumin and outcome. In three analyses the multivariate exceeded the univariate estimate by an average of 38%, while in the other five analyses the univariate estimate was larger by a mean of 24%. These observations confirm that adjustment for the effects of covariates can result in substantially altered effect size estimates.
Mortality
OR and CI estimates for mortality associated with a 10-g/L fall in serum albumin were obtained for 53 studies (Fig. 1 ). The pooled OR for these trials was 2.37 (CI 2.10 -2.68). Thus, the odds of death were increased by 137% with each 10-g/L decline in serum albumin, and the effect was statistically significant. Similarly, based on pooling within clinical indications, statistically significant increases in mortality odds of 102%, 116%, 180%, and 148% were observed for the hospitalization ( For the four categories of indications, the point estimates of OR were similar in magnitude and the pooled CI overlapped extensively. There was nevertheless evidence of significant overall statistical heterogeneity (P Ͻ .005), and additional possible contributors to heterogeneity (study design, patient age, multivariate analytic method, number of covariates, and study size) were investigated by sensitivity analysis ( Table 2 ). There were no substantial betweenstratum differences with respect to any of these variables, however, and hypoalbuminemia was significantly predictive of mortality in all strata. For instance, hypoalbuminemia was significantly associated with mortality both among retrospective and prospective cohort studies.
Thirteen included studies evaluated mortality but did not provide OR and CI estimates. 25, 32, 34, 36, [43] [44] [45] 51, 59, 72, 86, 88, 90 In eight of these studies, serum albumin was a significant Hypoalbuminemia independent predictor of mortality. Thus, the findings of these studies were qualitatively similar to those of the studies included in the meta-analysis shown in Figure 1 .
To evaluate potential confounding by malnutrition, 15 included cohort studies 57, 59, 61, 63, 65, 69, 70, 75, 78, 82, 90, 97, 102, 107, 110 assessed body mass index as a covariate. For the 10 of these studies with a mortality endpoint and available OR and CI data (see Table 2 ), the pooled OR for mortality per 10-g/L serum albumin decrement was 1.89 (CI 1.51-2.36). The association between hypoalbuminemia and mortality was also shown to be independent of other nutritional indices such body weight, dry weight, body fat percentage, weight loss, cachexia, midarm circumference, and biceps and triceps skinfold thicknesses. 18, 25, 26, 34, 49, 55, 60, 63, 65, 69, 88, 93, 97, 110 In seven studies the effect of hypoalbuminemia on mortality was assessed with the inflammatory marker C-reactive protein (CRP) as a covariate. 72, 74, 82, 83, 94, 97, 107 For six of these studies OR estimates were available, and the pooled OR was 2.77 (CI 1.66 -4.62), indicating that hypoalbuminemia remained a significant mortality predictor with the effects of CRP taken into account (see Table 2 ). The significant association between hypoalbuminemia and mortality also persisted when other markers of inflammation were evaluated as covariates (white blood cell count, lymphocyte count, neutrophil count, interleukin-6, interleukin-10, tumor necrosis factor-␣, ␤2-microglobulin, serum amyloid A, transferrin, and fibrinogen). 25, 26, 29, 32, 34, 44, 49, 50, 58, 63, 65, 69, 74, 82, 83, 95, 97 
Morbidity
Hypoalbuminemia was also an independent predictor of morbidity across all studies and within each of the four categories of clinical indications (Fig. 2) . Morbidity was reported as overall morbidity or as one or more types of individual complications, most frequently involving cardiovascular morbidity, infection, or organ dysfunction. Thus, morbidity did not constitute a single homogeneous outcome measure across studies, and the seriousness of particular complications evaluated was not necessarily similar.
The pooled OR for morbidity among all 18 studies assessing this endpoint was 1.89 (CI 1.59 -2.24), indicating a statistically significant 89% increase in odds of complications corresponding to a 10-g/L reduction in serum albumin. Significant increases in morbidity odds of 178%, 52%, 73%, and 102% were documented respectively among the subsets of studies involving hospitalization (OR 2.78; CI 1.30 -5.98), cardiac surgery (OR 1.52; CI 1.12-2.04), noncardiac surgery (OR 1.73; CI 1.67-1.79), and renal dysfunction (OR 2.02; CI 1.48 -2.74).
There was significant statistical heterogeneity with respect to the morbidity endpoint (P Ͻ .005). In sensitivity analyses between-stratum pooled estimates of OR did not differ notably, and CI overlapped extensively (see Table 2 ). Significantly increased morbidity odds per 10-g/L serum albumin decrement were apparent for all subsets of trials with data represented in Table 2 .
Morbidity was addressed in eight studies that could not be included in the meta-analysis of Figure 2 due to unavailability of OR and CI data. 24, 25, 27, 28, 30, 34, 56, 88 In seven of these studies serum albumin was found to be a significant independent predictor of morbidity.
In four studies with an OR estimate provided for morbidity and inclusion of body mass index as a covariate (see Table 2 ), hypoalbuminemia was significantly associated with morbidity (OR 1.42; CI 1.07-1.90). Hypoalbuminemia also remained a significant independent morbidity predictor in studies taking into account markers of nutritional status other than body mass index such as body weight, body surface area, degree of weight loss, rate of weight loss, triceps skinfold, midarm muscle circumference, and cachexia. 18, 24, 25, 34, 60, 61, 102 While none of the included studies assessed morbidity with CRP as a covariate, in three studies hypoalbuminemia was associated with significantly increased morbidity when other markers of inflammation were taken into account 
Length of Stay
Hypoalbuminemia was a significant independent predictor of prolongation in both ICU and hospital stay. Length of ICU stay was a subject of three included studies. 60, 78, 84 The pooled OR for ICU stay was 1.28 (CI 1.16 -1.40), indicating a significant 28% increase in odds for prolonged ICU stay per 10-g/L decrement in serum albumin.
OR and CI estimates for prolonged hospital stay were available from four included studies. 1, 39, 60, 78 The corresponding pooled OR was 1.71 (CI 1.33-2.21), revealing a significant hypoalbuminemia-related increase of 71% in odds of prolonged hospital stay. In five additional included studies, 30, 38, 41, 47, 71 length of hospital stay was evaluated, but OR and CI estimates were unavailable. Serum albumin was a significant independent predictor of prolonged hospital stay in all five studies.
Resource Utilization
In nine studies resource utilization was evaluated with respect to ventilatory support, 60, 78, 81, 106 postoperative trans-fusion, 57 and hospitalization (i.e., admission or readmission to hospital). 43, 76, 96, 97 The economic impact of each type of resource utilization was not quantified in the study reports and cannot be presumed to be similar in magnitude.
Among the eight studies supplying OR data, hypoalbuminemia significantly increased resource utilization by 66% per 10-g/L serum albumin decline (OR 1.66; CI 1.17-2.36). In the ninth study, no OR estimate was available, but hypoalbuminemia was significantly associated with increased resource utilization.
Other Endpoints
In two trials on the relation of hypoalbuminemia to treatment failure, 95, 96 the pooled OR was 2.07 (CI 0. 52-8.30 ). In one study hypoalbuminemia was predictive of significantly poorer quality of life. 104 The odds of overcoagulation were increased in hypoalbuminemic patients with venous thromboembolism (OR 3.60; CI 1.32-9.77). 109
Controlled Trials
Nine prospective controlled trials with 535 total patients conformed to all inclusion criteria. [111] [112] [113] [114] [115] [116] [117] [118] [119] The median num- Hypoalbuminemia ber of patients per trial was 38 (range 24 -219). Seven of the trials were randomized. 111,114 -119 None was unpublished. Characteristics of the included controlled trials are summarized in Table 3 . Four trials involved pediatric patients. [111] [112] [113] 116 For the adult studies the median patient age was 59 years (range . The median duration of follow-up for both adult and pediatric trials was 26 days (range 5-150).
Three trials involved some form of blinding. 114, 116, 119 The method of allocation concealment was adequate in four of six randomized trials, 114, 116, 118, 119 unclear in two, 115, 117 and inadequate in one. 111 Morbidity was an endpoint of all included trials except one. 117 In four trials individual controlgroup patients crossed over to albumin therapy. 114, 115, 117, 118 The median number of patients crossing over was 2.5 (range 2-6).
Pooled Morbidity
As shown in Figure 3 , the pooled OR for occurrence of one or more complications in individual patients was 0.74 (CI 0.36 -1.49). Thus, morbidity was lower among albumin recipients, but the effect was not statistically significant. The pooled odds ratio was similar after exclusion of the two nonrandomized trials (OR 0.81; CI 0.41-1.60). 112, 113 There was no evidence of publication bias (P ϭ .367). Among all control group patients, 48% (125/262) experienced one or more complications.
Dose Dependency
Significant between-trial heterogeneity was apparent with respect to the OR for complications (P ϭ .006), and possible sources of heterogeneity such as year of publication, duration of follow-up, and albumin dose as reflected by attained serum albumin level during therapy were investigated by meta-analysis regression. The OR for complications was not significantly related to either the year of publication (P ϭ .622) or duration of follow-up (P ϭ .220).
Pooled baseline serum albumin concentration did not differ significantly (P ϭ .79) between the albumin (24.4 Ϯ 1.4 g/L) and control group (24.5 Ϯ 1.4 g/L). Attained serum albumin level during therapy was reported in eight of nine trials. As shown in Figure 4 , 120 the OR for complications declined progressively as attained serum albumin level increased (P ϭ .002). In the five studies with an attained albumin level of more than 30 g/L, complications were less frequent in albumin recipients than control-group patients and vice versa in the three studies with an attained albumin level of less than 30 g/L. The between-study variance determined by method-of-moments estimator was 0.0815 in the meta-analysis regression as contrasted with 0.656 with no account taken of attained serum albumin level. Thus, the dose effect could explain 88% of total between-study variance. The significant observed dose-response relationship also persisted after exclusion of two early trials (P ϭ .026). 111, 112 Meta-analysis regression failed to reveal any significant relationship between morbidity and baseline se- 
DISCUSSION
Our meta-analysis is the first to assemble comprehensive evidence-based largely on recently reported data analyzed by multivariate methods-that addresses the long-standing debate over the clinical importance of hypoalbuminemia in the acutely ill. It also provides a novel quantitative model of dose dependency that may explain the disparate results obtained thus far in trials on the correction of hypoalbuminemia.
We found hypoalbuminemia to be a powerful, reproducible, dose-dependent, independent risk factor for poor out-come in the acutely ill. This association was striking both for its consistency and pervasiveness. Unfavorable sequelae associated with lower serum albumin were evident in hospitalized patients generally and in populations undergoing cardiac and noncardiac surgery or suffering from renal dysfunction. The hypoalbuminemia effect manifested itself across the full spectrum of clinical outcomes: mortality, morbidity, length of both ICU and hospital stay, and increased resource utilization. However, the evidence on length of stay, resource utilization, and certain other endpoints was substantially more limited than that on mortality and morbidity.
Because of the strength of the association and low cost of serum albumin assays, monitoring albumin levels has been advocated as a prognostic tool to identify higher-risk patients. 1, 18, 78 As vividly demonstrated in the largest included . Meta-analysis regression assessing the effect of attained serum albumin level on morbidity in controlled trials to evaluate the correction of hypoalbuminemia. Data points are scaled in proportion to precision. Incidence of complications was reported on a per-patient basis in six trials. [111] [112] [113] [114] [115] 118 The average number of complications per patient in these trials was 1.1. For the other three studies complications per patient were estimated from total complication data using 1.1 as the conversion factor. For analytic purposes the attained serum albumin reported in two early trials 111, 112 was adjusted downward by 13 g/L, corresponding to the difference between the mean serum albumin for healthy term infants using contemporary assay methods (35 g/L) 120 and the corresponding mean using older methodology (48 g/L), as documented in one of the two early trials. 111 Vol. 237 • No. 3 Hypoalbuminemia cohort study, involving 54,215 noncardiac surgery patients, 18 both mortality and morbidity continuously increased as serum albumin progressively decreased over the entire range of albumin levels between 22 and 46 g/L, and there was no evidence of any threshold above which albumin no longer substantially affected these outcomes. In light of these findings, clinical risk stratification strategies emphasizing only severe hypoalbuminemia (e.g., serum albumin Ͻ 25 g/L) may insufficiently recognize the increased risk of patients with higher albumin levels (e.g., 25-35 g/L).
Several limitations of our meta-analysis should be recognized. Reliance on multivariate analysis of cohort study results was a principal feature of the meta-analysis, and the included studies addressed a broad array of variables. Nevertheless, unidentified confounding variables may exist, and the possibility cannot be dismissed that the hypoalbuminemia effect is merely an epiphenomenon indicative of other pathologic processes, as has often been argued. Furthermore, among the included cohort studies both the numbers and types of covariates differed widely. Additionally, quantitative and qualitative differences were apparent among the complications assessed in both the included cohort studies and controlled trials. Because of these differences in the number, type and seriousness of complications quantitatively combined, the morbidity endpoint evaluated in our meta-analysis may with some justification be regarded as heterogeneous from a clinical point of view.
Our data indicate that two important potential confounding variables-malnutrition and inflammation-cannot fully explain the hypoalbuminemia effect. The malnourished state has long been recognized as a potential precipitating factor in the development of hypoalbuminemia. We found that the significant association between hypoalbuminemia and poor outcome persisted after adjustment for body mass index and other measures of nutritional status.
Growing attention has centered on the role of inflammatory processes in inducing hypoalbuminemia. By increasing vascular permeability, inflammatory mediators may promote escape of albumin into the extravascular space. Such mediators may also reprioritize hepatic protein synthesis in favor of acute phase reactants at the expense of albumin production. CRP, an acute phase protein produced by the liver, is one marker of inflammation that has been proposed to account for the association between hypoalbuminemia and poor outcome. 94 Nevertheless, we found the effects of hypoalbuminemia on outcome to be independent of CRP, as well as other markers of inflammation. Such observations make plain that inflammation, at least as manifested by altered levels of currently identified inflammatory markers, may contribute to reduced serum albumin levels but nevertheless cannot fully account for the association between hypoalbuminemia and poor outcome. It is possible, however, that other as yet undetectable derangements in patient inflammatory response might more completely explain the hypoalbuminemia effect.
Hypoalbuminemia may be causally related to poor out-come. A previous systematic review addressed the association between serum albumin and mortality in 10 cohort studies with multivariate analysis involving 55,965 healthy subjects and acutely ill patients. 7 In that review, circulating albumin concentration was inversely related to mortality risk in a progressive fashion over its entire range. The association persisted after adjustment for other known risk factors and pre-existing illness and exclusion of early mortality, and plausible biologic mechanisms underlying the effect were noted. The review prompted the conclusion that albumin may exert a direct protective effect. Our review, focusing exclusively on the acutely ill and addressing a wider range of outcomes, also supports this conclusion. Several mechanisms might help explain the apparent protective effects of serum albumin. Clearly, serum albumin plays diverse, complex, and important roles in maintaining physiologic homeostasis. At reduced albumin levels these homeostatic functions may be impaired, resulting in the development and/or progression of pathologic processes underlying poor outcome. The full spectrum of albumin biologic actions has as yet not been fully delineated and forms the center of an active field of recent research. Nevertheless, a number of its actions are well established, such as the ability to maintain normal colloid osmotic pressure (COP). Reduction in COP promotes edema formation. While many patients may tolerate edema adequately, others may be adversely affected, particularly by pulmonary, myocardial, or intestinal edema.
The ability of serum albumin to sustain COP may only be one of many possible protective effects of albumin. In a study of 145 patients with prolonged critical illness, hypoalbuminemia was associated with increased mortality, even though in these patients COP had been maintained by administration of artificial colloid. 121 Therefore, the hypoalbuminemia effect might be at least partly reliant on the additional properties of albumin such as its antioxidant and free radical-scavenging activity, capacity to prevent apoptosis, and affinity for binding lipids, drugs, toxic substances, and other ligands. [122] [123] [124] The antioxidant effects of albumin, for example, may translate into biologic protection of potential clinical relevance. Albumin decreased both hydrogen peroxide formation and reperfusion injury in isolated rat hearts. 125 It also prevented ischemic and hypoxic damage in isolated perfused rat livers. 126 Albumin inhibited peroxidation of erythrocyte membrane lipids in chronic hemodialysis patients. 127 Bilirubin bound to albumin substantially prolonged the survival of human ventricular heart muscle cells exposed to oxyradicals generated in situ. 128 Because of its high frequency in a broad range of pathologic conditions, hypoalbuminemia might plausibly be interpreted as a normal compensatory mechanism not requiring intervention. For instance, albumin redistribution into the interstitial space might provide protection from oxidative stress affecting extravascular tissues during disease states. Nonetheless, hypoalbuminemia-related reductions in COP, intravascular antioxidative reserve, binding activity, and other protective effects of albumin in the plasma compartment are difficult to view as a beneficial adaptation.
If indeed serum albumin exerts a net protective effect, then exogenous albumin therapy might benefit hypoalbuminemic patients. Furthermore, even if albumin level did primarily reflect other upstream pathologic processes, albumin therapy might nevertheless be effective as a downstream intervention to interrupt the chain of events culminating in poor outcome. Administration of purified albumin is clearly effective in raising serum albumin levels. 114 -116,118,129 Even in sepsis, a condition marked by increased vascular permeability, administered albumin can produce a prompt and sustained rise in serum albumin concentration. 130 Available evidence from controlled trials is, however, inconclusive as to the potential benefits to be derived from correcting hypoalbuminemia. In our meta-analysis, no significant overall reduction in morbidity was demonstrable. Nonetheless, the existing controlled trial evidence is limited. Furthermore, based on our meta-analysis regression, attained serum albumin level appears to be a major determinant of morbidity. Thus, the attained albumin level accounted for most of the between-study variance, indicating that the differences in morbidity results reported among the included controlled trials were predominantly due to dose effects. This analysis suggests the hypothesis that administering sufficient exogenous albumin to achieve a serum albumin level of more than 30 g/L might lessen morbidity in hypoalbuminemic patients. The significant within-study findings for the trials in our meta-analysis regression are consistent with this hypothesis.
In the three studies with an attained serum albumin level of less than 30 g/L, no within-study evidence was obtained of clinical benefit due to albumin therapy. 112, 115, 118 Conversely, such benefit was demonstrable in the four studies with a morbidity endpoint and an attained albumin level of more than 30 g/L. Specifically, in these studies with higher attained albumin levels, the albumin group experienced an acceleration of time to regain birthweight and fewer illnesses; 111 improved nutritional status and tolerance to enteral feeding; 113 fewer total hospital complications and lower frequencies of septicemia and pneumonia; 114 and greater relief of hypotension and shorter time to regain birthweight. 116 A morbidity benefit due to albumin therapy, if demonstrable, might improve the overall costs of care. Significant edema may limit mobilization and delay convalescence. In one included cohort study of 9,352 cardiac surgery patients, 66 hypoalbuminemia was predictive of postoperative infection, and ICU stay was increased over fivefold in patients developing infections (13.4 Ϯ 20.1 days vs. 2.5 Ϯ 3.8 days, P Ͻ .001). In another included cohort study of elderly hospitalized patients, hypoalbuminemia was associated with increased risk for a discharge diagnosis of delirium. 27 Patients with this diagnosis incurred average total hospital charges of $17,377 versus $11,946 for those without the diagnosis. Mean hospital stay was 23.7 days for patients with delirium compared with 13.6 days for nonde-lirious patients. Savings resulting from a reduced morbidity rate might exceed the acquisition cost of albumin.
Further well-designed, adequately powered controlled clinical trials are needed to resolve the question whether correcting hypoalbuminemia is beneficial. Pending the results of such future studies, there does appear to be a coherent rationale for albumin replacement therapy and no compelling basis to withhold albumin if it is deemed clinically appropriate in hypoalbuminemic patients.
